Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAbbVie Inc

AbbVie Inc

PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:29:15.165445Z
Market Cap
0.00M
P/E
0.21

Momentum Score

…

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
166.27
Low
240.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
286.00
Dividend Yield
4.53%
Revenue TTM
61160.00M
Revenue Per Share
34.57
Gross Profit TTM
43803.00M
Debt / Equity
20.46
ROE
62.25%
Net Debt
62495.00M
ROCE
19.01%
Diluted EPS TTM
6.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 3716.00M 6250.00M 13477.00M 12989.00M 3398.00M
Minority interest - - - - 21.00M
Net income 4278.00M 4820.00M 11782.00M 11468.00M 4556.00M
Selling general administrative 11089.00M 10704.00M 10084.00M 9772.00M 8067.00M
Selling and marketing expenses 2100.00M 2200.00M 2000.00M 2100.00M 1800.00M
Gross profit 39645.00M 37592.00M 41527.00M 40083.00M 30547.00M
Ebit 18332.00M 17660.00M 22957.00M 20891.00M 14677.00M
Ebitda 26718.00M 26358.00M 31424.00M 29412.00M 21148.00M
Depreciation and amortization 8386.00M 8698.00M 8467.00M 8521.00M 6471.00M
Operating income 9137.00M 12757.00M 22957.00M 20891.00M 14677.00M
Other operating expenses 47197.00M 41561.00M 42533.00M 40824.00M 40126.00M
Interest expense 2160.00M 1669.00M - 0.00M 0.00M
Tax provision - - - - -1224.00M
Interest income - - - - 2351.00M
Income tax expense -570.00M 1377.00M 1632.00M 1440.00M 1224.00M
Total revenue 56334.00M 54318.00M 58054.00M 56197.00M 45804.00M
Total operating expenses 30508.00M 24835.00M 26006.00M 24710.00M 24869.00M
Cost of revenue 16689.00M 16726.00M 16527.00M 16114.00M 15257.00M
Total other income expense net -5421.00M -6507.00M -9480.00M -7902.00M -11279.00M
Net income applicable to common shares - - 11782.00M 11468.00M 4556.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 135161.00M 134711.00M 138805.00M 146529.00M 150565.00M
Intangible assets 60068.00M 55610.00M 67439.00M 75951.00M 82876.00M
Other current assets 4927.00M 4932.00M 4401.00M 4993.00M 3562.00M
Total liab 131797.00M 124314.00M 121518.00M 131093.00M 137468.00M
Total stockholder equity 3325.00M 10360.00M 17254.00M 15408.00M 13076.00M
Other current liab 28822.00M 26796.00M 26604.00M 32312.00M 26385.00M
Common stock 18.00M 18.00M 18.00M 18.00M 18.00M
Retained earnings -7900.00M -1000.00M 4784.00M 3127.00M 1055.00M
Other liab - - 31716.00M 30982.00M 30401.00M
Good will 34956.00M 32293.00M 32156.00M 32379.00M 33124.00M
Other assets - 7769.00M 4834.00M 4096.00M 3825.00M
Cash 5524.00M 12814.00M 9201.00M 9746.00M 8449.00M
Total current liabilities 38749.00M 37841.00M 29538.00M 35194.00M 28661.00M
Current deferred revenue - -3688.00M - - -
Net debt 62495.00M 47584.00M -9201.00M -9746.00M -8449.00M
Short term debt 6982.00M 7357.00M - - 34.00M
Short long term debt total 68019.00M 60398.00M - - 77554.00M
Other stockholder equity 13132.00M 13647.00M 12452.00M 12263.00M 12003.00M
Property plant equipment - - 5672.00M 5872.00M 6143.00M
Total current assets 25582.00M 33002.00M 28463.00M 27928.00M 24173.00M
Net tangible assets - - -82341.00M -92922.00M -102924.00M
Short term investments 31.00M 2.00M 28.00M 84.00M 30.00M
Net receivables 10919.00M 11155.00M 11254.00M 9977.00M 8822.00M
Long term debt - - - - 77533.00M
Inventory 4181.00M 4099.00M 3579.00M 3128.00M 3310.00M
Accounts payable 2945.00M 3688.00M 2934.00M 2882.00M 2276.00M
Accumulated other comprehensive income -1925.00M -2305.00M - - -
Treasury stock - - - - -2264.00M
Non currrent assets other 8419.00M 7769.00M -105508.00M -114505.00M -122567.00M
Non current assets total 109579.00M 101709.00M 105508.00M 114505.00M 122567.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 92.00M -21.00M 1464.00M
Change to liabilities - - 1605.00M 1628.00M 1514.00M
Total cashflows from investing activities -20820.00M -2009.00M -623.00M -2344.00M -37557.00M
Net borrowings - - -12433.00M -8414.00M -2683.00M
Total cash from financing activities -5211.00M -17222.00M -24803.00M -19039.00M -11501.00M
Change to operating activities - - -264.00M -197.00M 134.00M
Net income 4278.00M 4863.00M 11836.00M 11542.00M 4616.00M
Change in cash -7290.00M 3613.00M -545.00M 1297.00M -31475.00M
Begin period cash flow 12814.00M 9201.00M 9746.00M 8449.00M 39924.00M
End period cash flow 5524.00M 12814.00M 9201.00M 9746.00M 8449.00M
Total cash from operating activities 18806.00M 22839.00M 24943.00M 22777.00M 17588.00M
Depreciation 8386.00M 8698.00M 8467.00M 8521.00M 6471.00M
Other cashflows from investing activities 671.00M -9.00M 774.00M 366.00M 1387.00M
Dividends paid 11025.00M 10539.00M 10043.00M 9261.00M 7716.00M
Change to inventory -319.00M -417.00M -686.00M -142.00M -40.00M
Change to account receivables 207.00M 66.00M -1455.00M -1321.00M -929.00M
Sale purchase of stock -1708.00M -1972.00M -1487.00M -934.00M -978.00M
Other cashflows from financing activities 172.00M -562.00M 1160.00M 570.00M 2876.00M
Change to netincome - - 4898.00M 4036.00M 6395.00M
Capital expenditures 974.00M 777.00M 695.00M 787.00M 798.00M
Change in working capital 249.00M -539.00M -2141.00M -1463.00M -969.00M
Stock based compensation 1421.00M 747.00M 671.00M 692.00M 753.00M
Other non cash items 4472.00M 9070.00M 6110.00M 3485.00M 6717.00M
Free cash flow 17832.00M 22062.00M 24248.00M 21990.00M 16790.00M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

AbbVie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

847 932 7900

https://www.abbvie.com

57000

Name Title Year Born
Mr. Richard A. Gonzalez Chairman & CEO 1954
Mr. Robert A. Michael Vice Chairman & Pres 1970
Ms. Laura J. Schumacher Vice Chairman of External Affairs & Chief Legal Officer 1963
Mr. Jeffrey Ryan Stewart Exec. VP & Chief Commercial Officer 1969
Mr. Scott T. Reents Exec. VP & CFO 1967
Dr. Azita Saleki-Gerhardt Ph.D. Exec. VP of Operations 1963
Dr. Thomas J. Hudson Sr. VP of R&D and Chief Scientific Officer 1962
Ms. Elizabeth Shea VP of Investor Relations NA
Mr. Perry C. Siatis Exec. VP, Gen. Counsel & Sec. NA
Mr. Timothy J. Richmond Exec. VP & Chief HR Officer 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…